
Opinion|Videos|November 15, 2024
First Line Treatment Decisions for Age-Related Macular Degeneration
Key Takeaways
Sumit Sharma, MD, FASRS asks the panel what they are using for first-line AMD treatment and what considerations factor into decision making, such as insurance coverage or risk of inflammation.
Advertisement
Episodes in this series

Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Increasing the knowledge base of GA is key to individualizing patient therapy
2
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved by FDA
3
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
4
Quantifying intermittent retinal capillary perfusion in RVO and PDR
5